期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

食管癌的EGFR靶向药物治疗现状 被引量：5

在线阅读 下载PDF
导出
摘要 食管癌全球年新发病约为482300例，年死亡406800例，中国食管癌粗发病率和粗死亡率均居世界第1位，发病世标率第6位，死亡世标率位于第12位。医学界对早、中期食管癌普遍采用手术或放疗为主、化疗为辅的治疗模式，对晚期患者则采用放、化疗联合的姑息治疗，但治疗效果不甚理想。
作者 王亚梅 王峰 彭方慧 杨晓利 樊青霞
机构地区 郑州大学第一附属医院肿瘤科
出处 《肿瘤基础与临床》 2013年第2期154-158,共5页 journal of basic and clinical oncology
关键词 食管癌 EGFR 靶向治疗
分类号 R735.1 [医药卫生—肿瘤]
作者简介 王亚梅（1988一），女，硕士在读，主要从事消化道肿瘤的基础与临床研究。E—mail：420759234@qq．com 通讯作者：樊青霞（1952一），女，教授，博士生导师，主要从事肿瘤的基础与临床研究。E—mail：fqx1003@126．com
  • 相关文献

参考文献26

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 2张思维,张敏,李光琳,魏文强,孟凡书,刘志才,郑荣寿,李霓,陈万青.2003～2007年中国食管癌发病与死亡分析[J].中国肿瘤,2012,21(4):241-247. 被引量：222
  • 3Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gone amplification in patients with esophageal squamous cell carcinoma [ J ]. Clin Cancer Res, 1996,2 (5) :909 - 914.
  • 4Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resec- ted esophageal adenocarcinoma [ J ]. J Gastrointest Surg, 2004,8 (4) :448 -453.
  • 5杨雅琼,李宗海.以EGFR为靶点的肿瘤分子靶向药物研究进展[J].中国生物工程杂志,2012,32(5):91-96. 被引量：24
  • 6Van Groeningen C, Pdchel D, Giaccone G. Gefitinib phase lI study in second line treatment of advanced esophageal cancer [ J ]. J Clin Oncol,2004,22(14S) : 4022.
  • 7Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive fac- tors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients [ J]. J Clin On- col,2006,24(10) : 1612 - 1619.
  • 8Ferry DR,Anderson M, Beddard K,et al. A phase II study of ge- fitinib monotherapy in advanced esophageal adenocarcinoma: evi- dence of gene expression, cellular, and clinical response [ J ]. Clin Cancer Res ,2007,13 ( 19 ) :5869 - 5875.
  • 9Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib,oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect pre- dicts clinical response [ J ]. Am J Clin Oncol, 2008,31 (4) : 329 - 334.
  • 10Juergens RA, Gibson MK,Yang SC,et al. Phase II study of neoad- juvant and adjuvant gefitinib ( G ) with neoadjuvant chemoradio- therapy (CRT) in operable esophageal adenocarcinoma (EAC) [ J]. J Clin Oncol,2010,28(Suppl) : Abstre14532.

二级参考文献26

  • 1Mendelsohn J, Baselga J. Status of epidermal growth factorreceptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003,21 (14) :2787-2799.
  • 2Assenat E, Desseigne F, Thezenas S, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase Ⅱtrial. Oncologist, 2011,16 ( 11 ) : 1557-1564.
  • 3Bonner J A, Harari P M, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 2010,11(1) :21-28.
  • 4Asai H, Shinozaki E, Nozaki A, et al. Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the treatment of unresectable metastatic colorectal cancer. Gan To Kagaku Ryoho, 2011,38(8) :1285-1291.
  • 5Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, et al. InterferordSTAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab [ Erbitux ( R ) ] efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol, 2011,39(6) :1455-1479.
  • 6Fhienelt C D, Bunn P A, Hanna Jr N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol, 2005,23 ( 34 ) : 8786-8793.
  • 7Kim G P, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics, 2008,2(2) :223-228.
  • 8Douillard J Y, Siena S, Cassidy J, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010,28 (31) :4697-4705.
  • 9Peeters M, Price T J, Cervantes A, et al. Randomized phase Ⅲ study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010,28(31 ) : 4706-4713.
  • 10Schrag D, Chung K Y, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst, 2005,97 (16) :1221-1224.

共引文献244

同被引文献46

  • 1于静萍,孙志强,倪新初,王坚,李毅,胡莉钧,李栋庆,孙苏平.食管癌患者放疗前后血清血管内皮生长因子变化的临床意义[J].中华放射医学与防护杂志,2011,31(6). 被引量：12
  • 2张阵阵,薛磊,王映红,吴彬,甘辉亮.试从系统论探讨腔镜食管癌根治手术的发展[J].海军医学杂志,2007,28(1):81-84. 被引量：3
  • 3胡巧英.食管癌新辅助放化疗结合手术与单纯手术治疗随机对照试验的Meta分析[J].中国肿瘤,2007,16(5):361-364. 被引量：22
  • 4Lazzarino AI, Nagpal K, Bottle A, et al. Open versus minimally invasive esophageetomy: trends of utilization and associated out- comes in England[ J]. Ann Surg,2010,252(2) :292-298.
  • 5Hulshof MC,Van Haaren,Van Lanschot JJ, et al. Preoperative che- moradiation combined with regional hyperthermia for patients with resectable esophageal cancer [ J ]. Int J Hyperthermia, 2009,25 ( 1 ) :79-85.
  • 6Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69-90.
  • 7Pech O, Giinter E, Dusemund F, et al. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: resultsfrom a referral center for early esophageal cancer [ J ]. Endoscopy, 2010,42(6) :456-461.
  • 8Walker AJ,Spier BJ,Perlman SB,et al. Integrated PET/CT fusion imaging and endoscopic ultrasound in the preoperative staging and evaluation of esophageal cancer [ J]. Mol Imaging Biol, 2011, 13 (1) :166-171.
  • 9Yoon MS, Nam TK, Lee JS, et al. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as prognosticator for survival in esophageal squamoua cell carcinoma[ J]. J Korean Med Sci,2011,26(4) :513-520.
  • 10Takala H, Sanrnio J, Wiik I-I, et al. HIF-Ia and VEGF are associat- ed with disease progression in esophageal carcinoma [ J ]. J Surg Res,2011 , 167 ( 1 ) :41 48.

引证文献5

二级引证文献64

肿瘤基础与临床
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部